Navigation Links
Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
Date:11/9/2011

BEIJING, Nov. 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the positive top-line results from its phase II clinical trial for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which causes hand, foot and mouth disease (HFMD).  The preliminary Phase II results for the EV71 vaccine showed a good immunogenicity and a favorable safety profile with no vaccine-related serious adverse event.

The phase II trial was designed as a single center, randomization, double blinded, and placebo controlled study and enrolled 540 healthy volunteers, comprised of infants from six months to thirty-five months old. On November 8, 2011, the unblinding conference for the phase II clinical data was held under the supervision from the Data Safety and Monitoring Committee (DSMC), and was attended by experts from the China State Food and Drug Administration (SFDA) and the China CDC. The phase II clinical results have provided the reference data for phase III clinical trial, including the vaccination schedule and dosage selection, based on which the proper dosage can be selected to enter into the phase III clinical trial. The purpose for the phase III clinical trial is to evaluate the efficacy of protection against HFMD caused by EV71 and is designed as a multi-center, randomized, double-blinded and control study.

Dr. Weidong Yin, Chairman and CEO, remarked, "The positive phase II results are the significant milestone in the development of our EV71 vaccine to address a significant unmet medical need in those area, where the young children are under the high risk of infection. Based on the phase II results, the proper dosage level can be selected to be utilized in the phase III clinical trial. We have started the preparation work for the phase III clinical trial, including dete
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
4. Sinovac Announces Plan to Launch Offering of Common Shares
5. Sinovac Announces Recent Developments
6. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
7. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
8. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
9. Sinovac Files Shelf Registration Statement
10. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
11. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 /PRNewswire-USNewswire/ ... often used to inflate sales of brand drugs ... Part D,  according to a new report ... Services Office of the Inspector General (OIG). Federal anti-kickback ... sales of goods that are subsidized by the ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... September 19, 2014 According ... Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise ... Advanced technologies - Global Forecast to 2019" published ... to reach $19,786.3 Million by 2019 from $14,240.0 ... from 2014 to 2019. Browse 74 ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... data presented today at the Society for Cardiovascular ... first to look at the use of highly ... detect restricted blood flow to the heart in ... Preliminary results from the ST-DETECT Trial using high-fidelity ...
... a compression clothing distributor, recently added three new ... Medical, Solaris and Gottfried are now available online through ... are used in lymphedema treatment. Lymphedema is a medical ... hands. Although it can be caused by a genetic ...
Cached Medicine Technology:New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 2New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 3BrightLife Direct Introduces 3 New Lymphedema Product Lines 2
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... September 19, 2014 According to a ... the embattled blood-thinner Xarelto, named as defendants in several ... Pleas, have moved the court to dismiss those suits ... have sufficient connection with Philadelphia.* The cases include, for ... (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which was ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- U.S. military troops deployed ... skin cancer, according to a new study. ... researchers revealed. In some cases, military personnel developed blisters ... color, shape or size of their moles since being ... risk factors for skin cancer, the study authors noted. ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- The U.S. Food and ... on Thursday. Trulicity is part of a class of once-a-week ... with type 2 diabetes. "Trulicity is a new ... existing treatment regimens to control blood sugar levels in the ... director of the FDA,s Office of Drug Evaluation II, said ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... associated with additional injury leading to structural and ... The injury induced during reperfusion is evolved a ... upon reoxygenation and a delayed phase. It is ... induces a cascade of series of cellular events ...
... blood clots are often recommended to stop these medications ... However, interruption of these medications can place patients at ... by Shai Friedland at the VA Palo Alto hospital ... without interrupting anticoagulation. Their study will be published on ...
... continuity after gastric resection. It seems that insufficient attention ... conditions affect the gastroduodenal system after distal gastric resection. ... duodenal suture dehiscence, but still many pathological mechanisms involved ... research article to be published on April 28, 2009 ...
... several other institutions worldwide, have pinpointed for the first ... endemic and epidemic mosquito-borne illness that is a rapidly ... The study, published in the May issue of ... the direct and indirect costs of dengue cases in ...
... Work, Money and the EconomySeven out of 10 ... 7 Economic pressures are having an increasing ... to a new survey by the American Psychological ... reporting significant stress related to work, money, housing ...
... of Directors of Tyco International Ltd. (NYSE: TYC ... (CHF) per share, payable on August 26, 2009, to shareholders ... 2009, subject to a required filing with the Swiss Commercial ... second installment of an annual dividend of CHF 0.93 per ...
Cached Medicine News:Health News:A new light on the mechanisms of early stage liver reperfusion injury 2Health News:Dengue fever costs billions in health care, lost productivity and absenteeism 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 3
Inquire...
... Used for the injection of contrast ... The dual lumen design eliminates the need ... designed to promote atraumatic passage into and ... layer of hydrophilic polymer that when activated, ...
Used for retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Medicine Products: